This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from AstraZeneca.

This activity is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Downloads
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Jarushka Naidoo

    Beaumont RCSI Cancer Centre, Dublin, Ireland

    Prof. Jarushka Naidoo is a consultant medical oncologist at Beaumont Royal College of Surgeons in Ireland (RCSI) Cancer Centre in Dublin, Ireland, professor of medical oncology at RCSI University of Medicine and Health Sciences, and an adjunct professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD, USA. read more

    Prof. Naidoo graduated with her medical degree (MB BCh BAO) from Trinity College Dublin, and completed internal medicine training and a medical oncology fellowship through the Royal College of Physicians of Ireland. She then completed an awarded advanced fellowship at Memorial Sloan Kettering Cancer Center in New York, and joined the faculty at Johns Hopkins University in 2015. At Johns Hopkins, she led a portfolio of clinical trials and translational studies focused on immunotherapy for lung cancer and immune-related adverse events, and was the co-chair of the multidisciplinary Johns Hopkins immune-related toxicity team.

    She recently returned to Ireland to lead the lung cancer programme at Beaumont RCSI Cancer Centre. She will also serve as the chair of the thoracic oncology committee for Cancer Trials Ireland, where she will direct and lead the national clinical trial programme for lung and thoracic cancers.

    Prof. Naidoo is the chair of the Immunotherapy Subcommittee of the NRG Clinical Trials Cooperative Group, serves on the ASCO NSCLC and Immune-Related Toxicity Guideline panels, and the scientific committees for ASCO, ESMO and IASLC World Lung Annual Meetings. She is the recipient of several grants and awards including a National Institutes of Health KL2 Clinical Scholar Award, Lung Cancer Foundation of America/IASLC Foundation Young Investigator Research Award and Irish Cancer Society’s Clinician Research Leadership Award 2022.

    Prof. Jarushka Naidoo discloses: Advisory board or panel fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, Kaleido Biosciences, Merck, Mirati Therapeutics, NGM Biopharmaceuticals, Pfizer, Roche and Takeda. Consultancy fees from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Elevation Oncology, Kaleido Biosciences, Merck, Mirati Therapeutics, NGM Biopharmaceuticals, Pfizer, Roche and Takeda. Grants/research support from Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Mirati, Novartis and Roche.
    Dr Rebecca Heist

    Massachusetts General Hospital Cancer Center, Boston, MA, USA

    Dr Rebecca Heist is a thoracic oncologist at the Massachusetts General Hospital (MGH) Cancer Center and associate professor of medicine at Harvard Medical School, MA, USA. read more

    Dr Heist’s research is focused on novel investigational agents in lung cancer and molecular targets in cancer. She is an active member of the Thoracic Oncology group and the Henri and Belinda Termeer Center for Targeted Therapies at MGH, and leads first-in-human clinical trials of investigational drugs, bridging the gap from translational science to phase I/Ib clinical trials.

    Dr Rebecca Heist discloses: Consultancy fees from AbbVie, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron and Sanofi. Grants/research support from AbbVie, Agios, Corvus Pharmaceuticals, Daiichi Sankyo, Erasca, Lilly, Mirati Therapeutics, Novartis and Turning Point.
    Dr Antonio Passaro

    European Institute of Oncology, Milan, Italy

    Dr Antonio Passaro is a medical oncologist at the Division of Thoracic Oncology, European Institute of Oncology in Milan, Italy. read more

    His main areas of research and clinical interest are predictive biomarkers, in particular EGFR and related targeted and immunotherapy agents, from discovery to validation in the clinical setting. He is also highly involved in the use of targeted agents in non-metastatic settings, either alone, or in a multimodality approach, for early or locally-advanced disease.

    Dr Passaro is involved in a portfolio of many clinical trials, both industry-funded and academic, investigating a range of novel lung cancer therapies. He has published more than 100 articles in peer-reviewed journals.  He also serves as a member of several national and international scientific committees.

    Dr Antonio Passaro discloses: Consultancy fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lilly, Merck Serono, MSD, Mundipharma, Novartis, Pfizer and Roche/Genentech. Advisory board or panel speaker from AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, ecancer, Janssen Pharmaceuticals, Lilly, Medscape, MSD and Takeda. Research support (institutional financial support for clinical trials) from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lilly, Merck Serono, Mirati, MSD, Pfizer, RMC Pharmaceutical Solutions and Roche/Genentech. Member of steering committee for trials funded by ArriVent Biopharma and Janssen Pharmaceuticals.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Start activity
     
    Videos Take CE/CME Test

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates

    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Japanese, Spanish.
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Outline the rationale for and mechanisms of action for antibody drug conjugates (ADCs) under investigation in NSCLC, and implications for patient selection
    • Evaluate the latest clinical trial data for ADCs in patients with advanced or metastatic NSCLC
    • Discuss incidence rates and severity of adverse events (AEs) associated with ADCs in metastatic NSCLC and potential role for therapeutic dose optimization strategies in AE management
    Overview

    In this activity, three oncology experts highlight the emerging role of ADCs in the treatment of patients with advanced NSCLC, including their mechanistic rationale and role of biomarkers in patient selection, the latest efficacy and safety data, and dose-finding strategies for optimal use in NSCLC. The discussion is guided by pre-canvassed questions provided by healthcare professionals involved in the management of patients with NSCLC.

    This activity has been designed to meet the educational needs of practising oncology specialists, lung cancer specialists and pathologists involved in the management of patients with NSCLC.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Japanese, Spanish.
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    CONFERENCE HUB

    Tarlatamab in pre-treated SCLC – DeLLphi-301 study: Luis Paz-Ares, EMSO 2023

    GO TO HUB

    touchIN CONVERSATION

    Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchMDT

    Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Luis Raez, WCLC 2021: Highlights from the Digital 2021 Conference

    GO TO HUB

    JOURNALS

    Bronchial Carcinoid Tumours in Children – A Review

    GO TO ARTICLE

    JOURNALS

    Unmet Needs in the Treatment of Metastatic Non-small-cell Lung Cancer

    GO TO ARTICLE

    Topics covered in this activity

    Lung Cancer
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 8 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from AstraZeneca.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 21 February 2023.

    Claim Credit
    touchPANEL DISCUSSION
    Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates

    You may also be interested in...

    touchPANEL DISCUSSION

    Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates

    LAUNCH ACTIVITY

    CONFERENCE HUB

    Luis Raez, WCLC 2021: Latest Advances in Immunotherapies and Targeted Therapies in Lung Cancer

    GO TO HUB

    CONFERENCE HUB

    Valsamo Anagnostou, WCLC 2021: A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer

    GO TO HUB

    touchTALKS

    A moving target: Assessing the role of EGFR-TKIs in early-stage NSCLC

    LAUNCH ACTIVITY

    JOURNALS

    Role of 4D Stereotactic Radiotherapy with the CyberKnife® System in the Treatment of Lung Cancer

    GO TO ARTICLE

    JOURNALS

    New Aspects in the Epidemiology of Lung Cancer – The Women’s Epidemic

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from AstraZeneca.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 21 February 2023.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72